KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment.

M Ambrosini, H Blons, S Garinet, C Mulot, D Le Corre, S Mouillet-Richard, F Pietrantonio, M Sroussi, C Lepage, P Laurent-Puig, J Taieb

ESMO Open 10(11) 105857

PMID41167084
PMCIDPMC12607000
DOI10.1016/j.esmoop.2025.105857
发表日期2025-10-30
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: The paradigm of molecular negative hyperselection, beyond RAS and BRAF, identifies metastatic colorectal cancer (mCRC) patients with the greatest benefit from anti-epidermal growth factor receptor (anti-EGFR) agents. We hypothesize that applying this model to stage III colon cancer (CC) might identify a subgroup deriving benefit from anti-EGFRs in the adjuvant setting. PATIENTS AND METHODS: We used a 'simplified PRESSING panel' grouping genomic alterations related to anti-EGFR primary resistance in mCRC, to select the proficient mismatch repair or microsatellite stable (pMMR/MSS) population of the randomized phase III PETACC-8 clinical trial, testing adjuvant FOLFOX ± cetuximab in resectable stage III CC. Patients without any tumor alterations in RAS/BRAF, or the simplified PRESSING panel were defined as 'hyperselected' (HS), whereas those with at least one such alteration were considered 'gene altered' (GA). RESULTS: Of 1421 eligible patients, 536 (37.7%) were HS and 885 (62.2%) GA. HS patients were more frequently male, with distal tumor of lower stage and grade. HS patients showed improved 5-year relapse-free survival (RFS) (81% versus 68%) and overall survival (OS) (89% versus 77%) as compared with GA patients. A statistically significant interaction was observed for RFS between molecular profile and treatment (P = 0.05). Among HS patients, adding cetuximab to FOLFOX yielded a 5-year RFS of 83% versus 78% with FOLFOX alone [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.55-1.19, P = 0.28]. Adding distal tumor location further improved the HR to 0.72 (P for interaction = 0.03). No significant interaction for OS was observed. In GA patients, the addition of cetuximab to FOLFOX was detrimental for RFS and OS. CONCLUSIONS: HS was prognostic for RFS and OS in patients with resected stage III pMMR/MSS CC and associated with a trend toward improved RFS with the addition of cetuximab to adjuvant FOLFOX. Conversely, cetuximab seems detrimental in patients with GA tumors. These data may help to improve patient selection in future adjuvant clinical trials testing anti-EGFR therapies.

KM 提取结果

3 个 Figure · 8 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 2

Figure 2 Kaplan–Meier curves for relapse-free survival (RFS) and overall survival (OS) according to molecular profile. (A) displays Kaplan–Meier curves for RFS in patients with hyperselected versus gene altered colon cancer; (B) displays Kaplan–Meier curves for OS in patients with hyperselected versus gene altered colon cancer. CI, confidence interval; GA, gene altered; HR, hazard ratio; HS, hyperselected.

A

relapse-free survival

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

overall survival

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Figure 3

Figure 3 Kaplan–Meier curves for relapse-free survival (RFS) and overall survival (OS) according to molecular profile and treatment arm. ( A) displays Kaplan–Meier curves for RFS in patients with hyperselected or gene altered colon cancer treated with FOLFOX or FOLFOX + cetuximab; (B) displays Kaplan–Meier curves for OS in patients with hyperselected or gene altered colon cancer treated with FOLFOX or FOLFOX + cetuximab. CI, confidence interval; GA, gene altered; HR, hazard ratio; HS, hyperselected.

A

Relapse-free survival (RFS)

Figure 3 · Panel A

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Overall survival (OS)

Figure 3 · Panel B

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure4 个面板

Figure 4

Figure 4 Kaplan–Meier curves for relapse-free survival (RFS) and overall survival (OS) according to molecular profile and treatment arm in patients with distal or proximal primary tumor location. (A and B) display Kaplan–Meier curves for RFS and OS in patients with hyperselected or gene altered distal colon cancer treated with FOLFOX or FOLFOX + cetuximab; (C and D) display Kaplan–Meier curves for RFS and OS in patients with hyperselected or gene altered proximal colon cancer treated with FOLFOX or FOLFOX + cetuximab. CI, confidence interval; GA, gene altered; HR, hazard ratio; HS, hyperselected.

A

relapse-free survival

Figure 4 · Panel A

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:extreme upward reversal
查看结果
B

overall survival

Figure 4 · Panel B

quality_warning 待 EXE 对齐 预期 4 条 已提取 1 条

Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

relapse-free survival

Figure 4 · Panel C

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel C 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

overall survival

Figure 4 · Panel D

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel D 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Study flowchart. Study flowchart illustrating the size of study population according to molecular profile and primary tumor location.
非 KM Figure